Longer-term open-label study of adjunctive riluzole in treatment-resistant depression
Open accessAbstract
Background While riluzole has been investigated for the treatment of depression, little is known about its longer-term efficacy and optimal treatment duration in treatment-resistant depression (TRD). The objective of this study is to characterize the longer-term outcome of adjunctive riluzole therapy for TRD in an open-label extension of an 8-week acute treatment trial.Methods The data from 66 patients with TRD who received adjunctive riluzole in a 12-week open-label extension phase were analyzed. Response rates (⩾50% reduction in the Mongomery-Asberg Depression Rating Scale [MADRS] score), relapse rates (a MADRS score of ⩾22 in patients who had previously achieved response), and adverse events were examined in patients who had achieved response at the end of the acute phase and those who had not.Results Among acute phase responders, the maintained response rate was 66.7% (8/12) and the relapse rate was 8.3% (1/12). In acute phase non-responders, the response rate was 24.1% (13/54). The most commonly reported adverse event was fatigue (9.1%). Three cases were considered serious adverse events; vomiting (n = 1), shortness of breath (n = 1), and aborted suicide attempt (n = 1).Limitations This longer-term study was open-label and uncontrolled. The sample size was relatively small.Conclusions Longer-term adjunctive riluzole appears relatively well tolerated and beneficial for maintaining previous response. Additionally, approximately one fourth of patients who did not respond to 8-week antidepressant treatment might respond if treated with riluzole for 12 weeks. Those findings warrant further investigation because adjunctive riluzole could represent an option for treatment of depression when standard antidepressants have failed.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Riluzole is currently in trials for combination therapy for treatment-resistant depression.
“This drug is currently in trials for combination therapy for treatment resistant depression.28”
From Bi-ancestral depression GWAS in the Million Veteran Program and meta-analysis in >1.2 million individuals highlight new therapeutic directions (2021) · cites this paper as [28]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962 · cited 1× · see citing works
“, 2007), (3) had an inadequate response to at least one but no greater than four adequate trials of an antidepressant, and (4) had at least moderate depressive symptom severity, with a Montgomery-Asberg Depression Rating Scale (MADRS) (Montgomery and Asberg, 1979) score ≥18 and an Inventory of Depressive Symptomatolog…”
BackgroundMolecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,501 · see citing works
The Inventory of Depressive Symptomatology (IDS): Psychometric properties
Rush, A. J., Gullion, C. M., Basco, M. R., Jarrett, R. B., & Trivedi, M. H. (1996) · Psychological Medicine · doi:10.1017/s0033291700035558 · Cited by 2,177 · cited 2× · see citing works
“, 2007), (3) had an inadequate response to at least one but no greater than four adequate trials of an antidepressant, and (4) had at least moderate depressive symptom severity, with a Montgomery-Asberg Depression Rating Scale (MADRS) (Montgomery and Asberg, 1979) score ≥18 and an Inventory of Depressive Symptomatolog…”
BackgroundSynaptic plasticity and depression: new insights from stress and rapid-acting antidepressants
Duman, R. S., Aghajanian, G. K., Sanacora, G., & Krystal, J. H. (2016) · Nature Medicine · doi:10.1038/nm.4050 · Cited by 1,750 · cited 1× · see citing works
“Furthermore, the glutamatergic system has been reported to play important roles in regulation of synaptic plasticity and to have a significant effect on mood, cognition, and reward circuitry (Abdallah et al., 2014; Duman et al., 2016).”
BackgroundThe pharmacology and mechanism of action of riluzole
Doble, A. (1996) · Neurology · doi:10.1212/wnl.47.6_suppl_4.233s · Cited by 700 · cited 1× · see citing works
“Its mechanism of action is thought to be inhibition of presynaptic release of glutamate via inactivation of voltage-dependent sodium channels on glutamatergic nerve terminals (Pittenger et al., 2008; Doble, 1996).”
BackgroundKetamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression.
Newport, D. J., Carpenter, L. L., McDonald, W. M., Potash, J. B., Tohen, M., Nemeroff, C. B., & The APA Council of Research Task Force on Novel Biomarkers and Treatments (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15040465 · Cited by 598 · cited 1× · see citing works
“, 2017), the limited efficacy of current drug treatments for depression represents an extraordinary need for discovering and applying novel antidepressant mechanisms beyond the monoamines (Papakostas and Ionescu, 2015; Newport et al., 2015; Chang and Fava, 2010).”
BackgroundManji, H. K., Quiroz, J. A., Sporn, J., Payne, J. L., Denicoff, K. D., Gray, N. A., Zarate, C. A., & Charney, D. S. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00117-3 · Cited by 499 · cited 6× · see citing works
“Furthermore, BDNF contributes to the cellular processes underlying neuronal plasticity and restoration/enhancement of neural connectivity mechanisms (Manji et al., 2003).”
BackgroundInfluentialLener, M. S., Niciu, M. J., Ballard, E. D., Park, M., Park, L. T., Nugent, A. C., & Zarate, C. A. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.05.005 · Cited by 468 · cited 1× · see citing works
“In recent reports, brain network dysfunction associated with the glutamatergic system has been identified in both animal and human studies of depression (Lener et al., 2017).”
BackgroundBanasr, M., Chowdhury, G. M. I., Terwilliger, R., Newton, S. S., Duman, R. S., Behar, K. L., & Sanacora, G. (2010) · Molecular Psychiatry · doi:10.1038/mp.2008.106 · Cited by 458 · cited 2× · see citing works
“Moreover, riluzole has the longer-term potential to provide neuroprotection and neuroplasticity, especially due to the increased activity of glutamate transporters (Banasr et al., 2010) and expression and release of brain-derived neurotrophic factor (BDNF) (Machado-Vieira et al.”
BackgroundFava, M., Evins, A. E., Dorer, D. J., & Schoenfeld, D. A. (2003) · Psychotherapy and Psychosomatics · doi:10.1159/000069738 · Cited by 452 · cited 5× · see citing works
“We therefore examined the longer-term efficacy of adjunctive riluzole in an open-label extension phase of the multicenter acute-phase double-blind trial that had shown no effects of riluzole in the randomized 8-week sequential parallel comparison design (SPCD) phase (Mathew et al., 2017).”
MethodInfluentialSAFTEE: a technique for the systematic assessment of side effects in clinical trials.
Levine, J., & Schooler, N. (1986) · PubMed · Cited by 329 · see citing works
An Open-Label Trial of Riluzole in Patients With Treatment-Resistant Major Depression
Zarate, C. A., Payne, J. L., Quiroz, J. A., Sporn, J., Denicoff, K. K., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.1.171 · Cited by 324 · see citing works
Assessing impairment in patients with panic disorder: the Sheehan Disability Scale
Leon, A. C., Shear, M. K., Portera, L., & Klerman, G. L. (1992) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/bf00788510 · Cited by 319 · cited 11× · see citing works
“CGI-I, Clinical Global Impressions-Improvement; CPFQ, Cognitive and Physical Functioning Questionnaire; IDS-SR, Inventory of Depressive Symptomatology Self Report; LOCF, Last observation carried forward; MADRS, Montgomery-Asberg Depression Rating Scale; n.a., Not available; PBO-R, Placebo responder; RIL-R, Riluzole re…”
InfluentialKatoh‐Semba, R., TAKEUCHI, I. K., Semba, R., & Kato, K. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.69010034.x · Cited by 308 · cited 5× · see citing works
“Furthermore, BDNF contributes to the cellular processes underlying neuronal plasticity and restoration/enhancement of neural connectivity mechanisms (Manji et al., 2003).”
BackgroundInfluentialZarate, C. A., Quiroz, J. A., Singh, J. B., Denicoff, K. D., Jesus, G. D., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.11.023 · Cited by 257 · see citing works
Wang, S.-J., Wang, K., & Wang, W.-C. (2004) · Neuroscience · doi:10.1016/j.neuroscience.2004.01.019 · Cited by 210 · cited 1× · see citing works
“Riluzole also inhibits voltage-gated calcium channels, leading to reduction of calcium influx and glutamate release (Wang et al., 2004).”
BackgroundDebono, M.-W., Guern, J. L., Canton, T., Doble, A., & Pradier, L. (1993) · European Journal of Pharmacology · doi:10.1016/0014-2999(93)90147-a · Cited by 210 · cited 1× · see citing works
“Moreover, riluzole can act directly on the Nmethyl-D-aspartate (NMDA) receptor, α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) receptor, and kainate receptor (Debono et al., 1993; Zona et al., 2002; Albo et al., 2004).”
BackgroundGlutamate Metabolism in Major Depressive Disorder
Abdallah, C. G., Jiang, L., De Feyter, H. M., Fasula, M., Krystal, J. H., Rothman, D. L., Mason, G. F., & Sanacora, G. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2014.14010067 · Cited by 200 · cited 1× · see citing works
“Furthermore, the glutamatergic system has been reported to play important roles in regulation of synaptic plasticity and to have a significant effect on mood, cognition, and reward circuitry (Abdallah et al., 2014; Duman et al., 2016).”
BackgroundSanacora, G., Kendell, S. F., Levin, Y., Simen, A. A., Fenton, L. R., Coric, V., & Krystal, J. H. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.08.037 · Cited by 199 · cited 1× · see citing works
“Although riluzole has shown promise as monotherapy or augmentation therapy in treatmentresistant mood disorders in open-label human studies (Zarate et al., 2004; Zarate et al., 2005; Sanacora et al., 2007; Brennan et al., 2010), it was not more effective than placebo for the treatment of bipolar depression in the two…”
BackgroundRiluzole in the Treatment of Mood and Anxiety Disorders
Pittenger, C., Coric, V., Banasr, M., Bloch, M., Krystal, J. H., & Sanacora, G. (2008) · CNS Drugs · doi:10.2165/00023210-200822090-00004 · Cited by 177 · cited 1× · see citing works
“Its mechanism of action is thought to be inhibition of presynaptic release of glutamate via inactivation of voltage-dependent sodium channels on glutamatergic nerve terminals (Pittenger et al., 2008; Doble, 1996).”
BackgroundWilkinson, S. T., & Sanacora, G. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2018.11.007 · Cited by 173 · cited 1× · see citing works
“For these reasons, drugs that have an impact on the glutamatergic system have been investigated as potential new antidepressants (Wilkinson and Sanacora, 2018).”
BackgroundSelf-citationMachado-Vieira, R., Manji, H. K., & Zarate, C. A. (2009) · The Neuroscientist · doi:10.1177/1073858409336093 · Cited by 171 · cited 8× · see citing works
“Furthermore, BDNF contributes to the cellular processes underlying neuronal plasticity and restoration/enhancement of neural connectivity mechanisms (Manji et al., 2003).”
BackgroundInfluentialBrennan, B. P., Hudson, J. I., Jensen, J. E., McCarthy, J., Roberts, J. L., Prescot, A. P., Cohen, B. M., Pope, H. G., Renshaw, P. F., & Öngür, D. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.191 · Cited by 168 · cited 1× · see citing works
“Although riluzole has shown promise as monotherapy or augmentation therapy in treatmentresistant mood disorders in open-label human studies (Zarate et al., 2004; Zarate et al., 2005; Sanacora et al., 2007; Brennan et al., 2010), it was not more effective than placebo for the treatment of bipolar depression in the two…”
BackgroundFava, M., Mischoulon, D., Iosifescu, D., Witte, J., Pencina, M., Flynn, M., Harper, L., Levy, M., Rickels, K., & Pollack, M. (2012) · Psychotherapy and Psychosomatics · doi:10.1159/000332050 · Cited by 141 · cited 10× · see citing works
“Background: While riluzole has been investigated for the treatment of depression, little is known about its longer-term efficacy and optimal treatment duration in treatment-resistant depression (TRD).”
ResultInfluentialSelf-citationD, M. F. M., Iosifescu, D. V., Pedrelli, P., & Baer, L. (2009) · Psychotherapy and Psychosomatics · doi:10.1159/000201934 · Cited by 135 · cited 11× · see citing works
“CGI-I, Clinical Global Impressions-Improvement; CPFQ, Cognitive and Physical Functioning Questionnaire; IDS-SR, Inventory of Depressive Symptomatology Self Report; LOCF, Last observation carried forward; MADRS, Montgomery-Asberg Depression Rating Scale; n.a., Not available; PBO-R, Placebo responder; RIL-R, Riluzole re…”
MethodInfluentialTowards new mechanisms: an update on therapeutics for treatment-resistant major depressive disorder
Papakostas, G. I., & Ionescu, D. (2015) · Molecular Psychiatry · doi:10.1038/mp.2015.92 · Cited by 122 · cited 2× · see citing works
“…disorder (Baldessarini et al., 2017), the limited efficacy of current drug treatments for depression represents an extraordinary need for discovering and applying novel antidepressant mechanisms beyond the monoamines (Papakostas and Ionescu, 2015; Newport et al., 2015; Chang and Fava, 2010).”
BackgroundRiluzole in psychiatry: a systematic review of the literature
Zarate, C. A., & Manji, H. K. (2008) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.4.9.1223 · Cited by 104 · cited 7× · see citing works
“Furthermore, BDNF contributes to the cellular processes underlying neuronal plasticity and restoration/enhancement of neural connectivity mechanisms (Manji et al., 2003).”
BackgroundInfluentialGourley, S. L., Espitia, J. W., Sanacora, G., & Taylor, J. R. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2403-4 · Cited by 85 · cited 1× · see citing works
“transporter 2 (EAAT2) expression and function in preclinical rodent studies, which may prevent excitotoxic effects of extracellular glutamate and protect neurons from stress- or injury-related insults (Banasr et al., 2010; Gourley et al., 2012).”
BackgroundMorbidity in depressive disorders
Baldessarini, R. J., Forte, A., Selle, V., Sim, K., Tondo, L., Undurraga, J., & Vázquez, G. H. (2017) · Psychotherapy and Psychosomatics · doi:10.1159/000448661 · Cited by 63 · cited 1× · see citing works
“Given the extraordinary morbidity of major depressive disorder (Baldessarini et al., 2017), the limited efficacy of current drug treatments for depression represents an extraordinary need for discovering and applying novel antidepressant mechanisms beyond the monoamines (Papakostas and Ionescu, 2015; Newport et al.”
BackgroundModulation of AMPA receptors in spinal motor neurons by the neuroprotective agent riluzole
Albo, F., Pieri, M., & Zona, C. (2004) · Journal of Neuroscience Research · doi:10.1002/jnr.20244 · Cited by 61 · cited 1× · see citing works
“Moreover, riluzole can act directly on the Nmethyl-D-aspartate (NMDA) receptor, α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) receptor, and kainate receptor (Debono et al., 1993; Zona et al., 2002; Albo et al., 2004).”
BackgroundPapakostas, G. I., D, M. F. M., Baer, L., Swee, M. B., Jaeger, A., Bobo, W. V., & Shelton, R. C. (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.14101251 · Cited by 58 · cited 1× · see citing works
“These outcomes might be at a similar level to that of atypical antipsychotic augmentation in patients with TRD (Fava et al., 2012; Papakostas et al., 2015; Brunner et al., 2014).”
ResultSalardini, E., Zeinoddini, A., Mohammadinejad, P., Ardakani, M. R. K., Zahraei, N., Zeinoddini, A., & Akhondzadeh, S. (2016) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2016.01.003 · Cited by 53 · cited 1× · see citing works
“In contrast, a placebo-controlled trial in 60 inpatients with major depressive disorder (MDD) found augmentation of citalopram with riluzole was superior to the combination of citalopram and placebo (Salardini et al., 2016).”
ResultBrunner, E., Tohen, M. F., Osuntokun, O. O., Landry, J., & Thase, M. E. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.101 · Cited by 50 · cited 10× · see citing works
“Background: While riluzole has been investigated for the treatment of depression, little is known about its longer-term efficacy and optimal treatment duration in treatment-resistant depression (TRD).”
ResultInfluentialThe future of psychopharmacology of depression.
Chang, T., & Fava, M. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10m06223blu · Cited by 50 · cited 1× · see citing works
“, 2017), the limited efficacy of current drug treatments for depression represents an extraordinary need for discovering and applying novel antidepressant mechanisms beyond the monoamines (Papakostas and Ionescu, 2015; Newport et al., 2015; Chang and Fava, 2010).”
BackgroundSelf-citationMathew, S. J., Gueorguieva, R. V., Brandt, C., D, M. F. M., & Sanacora, G. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.106 · Cited by 47 · see citing works
Self-citationA Double-Blind, Placebo-Controlled, Pilot Study of Riluzole Monotherapy for Acute Bipolar Depression
Park, L. T., Lener, M. S., Hopkins, M., Iadorola, N., Machado‐Vieira, R., Ballard, E. D., Nugent, A. C., & Zarate, C. A. (2017) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000693 · Cited by 34 · see citing works
Is There a Placebo Problem in Antidepressant Trials?
Yang, H., Cusin, C., & Fava, M. (2005) · Current Topics in Medicinal Chemistry · doi:10.2174/156802605774297092 · Cited by 32 · cited 1× · see citing works
“placebo, we showed that the majority of improvement during antidepressant and placebo treatment occurred in the first half of the antidepressant trial regardless of the duration (Yang et al., 2005).”
BackgroundSelf-citationKainate‐induced currents in rat cortical neurons in culture are modulated by riluzole
Zona, C., Cavalcanti, S., Sarro, G. D., Siniscalchi, A., Marchetti, C., Gaetti, C., Costa, N., Mercuri, N. B., & Bernardi, G. (2002) · Synapse · doi:10.1002/syn.10040 · Cited by 30 · see citing works
Wilkinson, S. T., Kiselycznyk, C., Banasr, M., Webler, R. D., Haile, C. N., & Mathew, S. J. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.08.075 · Cited by 24 · see citing works
Self-citationCitalopram 20 mg, Citalo ram 40 mg and Placebo in the Prevention of Relapse of Major Depression
Montgomery, S., & Rasmussen, J. G. (1992) · International Clinical Psychopharmacology · doi:10.1097/00004850-199206005-00008 · Cited by 19 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Levey, D. F., Stein, M. B., Wendt, F. R., Pathak, G. A., Zhou, H., Aslan, M., Quaden, R., Harrington, K. M., Nuñez, Y. Z., Overstreet, C., et al. (2021) · Nature Neuroscience · doi:10.1038/s41593-021-00860-2 · Cited by 422 · see citing works
Harmonizing the Neurobiology and Treatment of Obsessive-Compulsive Disorder
Goodman, W. K., Storch, E. A., & Sheth, S. A. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20111601 · Cited by 271 · see citing works
The stressed synapse 2.0: pathophysiological mechanisms in stress-related neuropsychiatric disorders
Sanacora, G., Yan, Z., & Popoli, M. (2022) · Nature Reviews Neuroscience · doi:10.1038/s41583-021-00540-x · Cited by 197 · see citing works
Fehlings, M. G., Badhiwala, J. H., Ahn, H., Farhadi, H. F., Shaffrey, C. I., Nassr, A. N., Mummaneni, P. V., Arnold, P. M., Jacobs, W. B., Riew, K. D., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30407-5 · Cited by 94 · see citing works
Is depression the missing link between inflammatory mediators and cancer?
Polityńska, B., Pokorska, O., Wojtukiewicz, A. M., Sawicka, M., Mysliwiec, M., Honn, K. V., Tucker, S. C., & Wojtukiewicz, M. Z. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108293 · Cited by 80 · see citing works
Glutamatergic Modulators for Major Depression from Theory to Clinical Use
McIntyre, R. S., & Jain, R. (2024) · CNS Drugs · doi:10.1007/s40263-024-01114-y · Cited by 69 · see citing works
“Riluzole can inhibit the release of presynaptic glutamate and interact with ionotropic receptors [84].”
BackgroundResultTsai, S., Hsu, P., Chen, Y., Hossain, M. S., Chen, P., Tzeng, S., Chen, P. S., & Kuo, Y. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01787-1 · Cited by 63 · see citing works
Colwell, M., Tagomori, H., Chapman, S., Gillespie, A. L., Cowen, P. J., Harmer, C. J., & Murphy, S. E. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-02249-6 · Cited by 63 · see citing works
“The NMDA antagonist riluzole has wellreplicated antidepressant effects [117, 118], but did not improve self-reported cognitive impairment when administered as an adjunct to antidepressants [118].”
BackgroundGuglielmo, R., & Hasler, G. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104906 · Cited by 16 · see citing works
Treatment of Depression in Huntington’s Disease: A Systematic Review
Zadegan, S. A., Ramirez, F., Reddy, K. S., Sahin, O., Rocha, N. P., Teixeira, A. L., & Furr-Stimming, E. E. (2024) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.20230120 · Cited by 14 · see citing works
Bansal, Y., Fee, C., Misquitta, K. A., Codeluppi-Arrowsmith, S. A., Sibille, E. L., Berman, R., Coric, V., Sanacora, G., & Banasr, M. (2023) · Complex Psychiatry · doi:10.1159/000529534 · Cited by 12 · see citing works
Emerging role of glutamate in the pathophysiology and therapeutics of Gulf War illness
Wang, X., Ali, N., & Lin, C. G. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119609 · Cited by 11 · see citing works
Experimental Therapeutics in Treatment-Resistant Major Depressive Disorder
Kaur, M., & Sanches, M. (2021) · Journal of Experimental Pharmacology · doi:10.2147/jep.s259302 · Cited by 10 · see citing works
Sun, Z., Liu, X., An, P., & Zhang, B. (2023) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2023.2223949 · Cited by 8 · see citing works
Astrocytes in Bipolar Disorder
Butt, A. M., & Rivera, A. D. (2021) · Advances in neurobiology · doi:10.1007/978-3-030-77375-5_5 · Cited by 8 · see citing works
Treatment resistant depression
Vaccarino, S. R., & Kennedy, S. H. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-821033-8.00003-4 · Cited by 7 · see citing works
Srivastava, J., Yadav, J., & Dubey, N. (2026) · Cognitive Neurodynamics · doi:10.1007/s11571-026-10446-y · Cited by 3 · see citing works
TRANSPORTERS AS THERAPEUTIC TARGETS IN HUMAN DISEASES
Jones, R. S., & Chen, E. C. (2022) · Wiley eBooks · doi:10.1002/9781119739883.ch24 · Cited by 1 · see citing works
New Pharmacological Therapeutic Approaches for Depressive Disorders: A Systematic Review
de Aquino, T. L., Libório, J. R., Bezerra, A. L. M. S., Cavalcante, G. M. E., Fern, D., Duarte, A. B., Martin, A. L. D. A. R., de Paula, J. D. A., & Neto, M. L. R. (2021) · Archives of Medicine · doi:10.36648/1989-5216.21.13.32
New Pharmacological Therapeutic Approaches for Depressive Disorders: A Systematic Review
de Aquino, T. L., Libório, J. R., Bezerra, A. L. M. S., Cavalcante, G. M. E., Duarte, D. F. B., Martin, A. L. D. A. R., de Paula, J. D. A., & Neto, M. L. R. (2021) · Journal of Anxiety & Depression · doi:10.46527/2582-3264.138
- Authors
- Sakurai, H., Dording, C., Yeung, A., Foster, S., Jain, F., Chang, T., Trinh, N.-H., Bernard, R., Boyden, S., Iqbal, S. Z., Wilkinson, S. T., Mathew, S. J., Mischoulon, D., Fava, M., & Cusin, C.
- Affiliations
- Keio University (JP)
- Massachusetts General Hospital (US)
- Michael E. DeBakey VA Medical Center (US)
- Yale University (US)
- Harvard University (US)
- Corresponding author
- Cusin, Cristina
- ORCID
- Venue
- Journal of Affective Disorders
- Publisher
- Elsevier BV
- Published
- 2019-11
- Volume
- 258
- Pages
- 102-108
- ISSN
- 0165-0327 (ISSN-L)
- PMC
- PMC6710149
- OpenAlex
- W2954845150
- Cited by
- 20
- References
- 40
- Citations by year
- 2026: 1 · 2024: 2 · 2023: 2 · 2022: 5 · 2021: 8 · 2020: 2
- FWCI
- 2.32
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Affective Disorders (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Agency for Healthcare Research and Quality (K12HS023000)
- Veterans Administration Medical Center
- American Foundation for Suicide Prevention
- National Institute of Mental Health (R01MH085050, R01MH085055, R01MH085054)
- Brain and Behavior Research Foundation
- National Alliance for Research on Schizophrenia and Depression
- U.S. Department of Veterans Affairs
- State of Connecticut Department of Mental Health and Addiction Services
- National Institutes of Health
- Stichting voor de Technische Wetenschappen
- Topics
- Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Social Sciences › Psychology › Clinical Psychology › Psychological Treatments and Disorders
- Keywords
- riluzole, treatment-resistant depression, adjunctive therapy, long-term efficacy, relapse, response maintenance, adverse events, fatigue, antidepressant non-responders
- MeSH terms
- Adult, Antidepressive Agents, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Time Factors, Treatment Outcome, Riluzole, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
